Mitochondrial calcium homeostasis is a tightly controlled process that is required for a variety of cellular functions. The mitochondrial calcium uniporter complex plays a critical role in this process. MICU2 is a major component of the mitochondrial calcium uniporter complex and its deficiency has been shown to impair mitochondrial calcium [Ca 2 + ] m homeostasis although the exact mechanism remains unclear. We used exome sequencing, positional mapping, and functional characterization of MICU2 deficiency to investigate the role of MICU2 in calcium homeostasis. Using combined autozygome/exome analysis, a homozygous truncating mutation in MICU2 was found to fully segregate with a neurodevelopmental disorder in the form of severe cognitive impairment, spasticity, and white matter involvement in a multiplex consanguineous family. Patient-derived MICU2-deficient cells displayed impaired [Ca 2 + ] m homeostasis, with associated increase in mitochondrial sensitivity to oxidative stress, and abnormal regulation of inner mitochondrial membrane potential. This is the first demonstration of MICU2 deficiency in humans, which we suggest causes a distinct neurodevelopmental phenotype secondary to impaired mitochondrial calcium uniporter-mediated regulation of intracellular calcium homeostasis.
Introduction
Mitochondria are membrane-bound organelles that are indispensable to energy production and a multitude of other essential cellular functions (Duchen and Szabadkai, 2010) . Mitochondrial calcium homeostasis is necessary for several of these functions e.g. cell metabolism, cell death and calcium signalling (McCormack et al., 1990; Rizzuto and Pozzan, 2006; Giacomello et al., 2007; Szabadkai and Duchen, 2008) .
The potential created by the electron transport chain across the mitochondrial membrane makes these organelles susceptible to calcium overload through the influx of cytosolic calcium into the matrix via the mitochondria calcium uniporter (MCU) (Mallilankaraman et al., 2012b; Csordá s et al., 2013; Patron et al., 2014) . MCU is a selective calcium ion channel complex localized to the inner mitochondrial membrane (Kirichok et al., 2004) . It comprises the pore-forming subunit, three major regulatory subunits: EMRE, MICU1 and MICU2, as well as MICUR1 and MCUb (De Stefani and Rizzuto, 2014; Foskett and Madesh, 2014; . Each of the regulatory components has been studied in vitro, and available data suggest, according to one model, that while MCU is localized to the inner mitochondrial membrane, it senses calcium both in the matrix via EMRE, and intermembrane space via MICU1 and MICU2. The model also suggests that EMRE bridges MICU1 and MICU2 as well, and regulates their inhibition of the uniporter Vais et al., 2016) . However, there are conflicting data on whether MICU1 inhibits, stimulates, or has a dual influence on the uniporter activity (Perocchi et al., 2010; Alam et al., 2012; de la Fuente et al., 2014) . The role of MICU2 is less well studied, although it is thought to be largely inhibitory in its effect on MCU activity (Patron et al., 2014; Matesanz-Isabel et al., 2016) .
Despite the apparent importance of MCU in [Ca 2 + ] m homeostasis, our knowledge of its relevance to human health is limited to two studies in which recessive mutations in MICU1 were identified in patients with a mitochondrial phenotype (Logan et al., 2014; Lewis-Smith et al., 2016) . Specifically, these patients had myopathy, ophthalmoplegia and basal ganglia involvement typical of mitochondrial encephalomyopathy (Logan et al., 2014) . They appear to lack lactic acidosis and have normal respiratory chain analysis despite the abnormal mitochondrial morphology (Logan et al., 2014) . Abnormal baseline and triggerinduced [Ca 2 + ] m was demonstrated in patient cells, and the authors concluded this could be the basis of the phenotype observed in their patients (Logan et al., 2014; Bhosale et al., 2017) .
The reported dependence of MICU2 on MICU1 for stability suggests that their deficiency states may result in a similar phenotype although no patients with MICU2 mutations have been reported to date. In this study, we describe the first human patients with MICU2 deficiency, characterize the pathological effect at the cellular level, and compare and contrast MICU1 and MICU2 deficiency states at the phenotypic and molecular levels.
Materials and methods

Human subjects
Patients were evaluated clinically by a board certified clinical geneticist and neurologist. Informed consent was obtained from parents and blood was collected from the available family members for enrolment in an IRB-approved research protocol (KFSRHC RAC#2121053). Skin biopsy from both patients was also obtained to derive patient fibroblasts for functional characterization of the mutation.
Autozygome analysis
DNA samples were genotyped using Axiom SNP Chip as per the manufacturer's instructions. Genotyping files were analysed using AutoSNPa (http://dna.leeds.ac.uk/autosnpa) to identify runs of homozygosity (ROH) that were 42 Mb in length as surrogates of autozygosity (Alkuraya, 2010) . Only autozygous intervals that are exclusively shared by the two affected children were considered as positional candidates.
Exome sequencing and variant interpretation
Exome capture was performed using TruSeq Exome Enrichment kit (Illumina) following the manufacturer's protocol. Samples were prepared as an Illumina sequencing library, and in the second step, the sequencing libraries were enriched for the desired target using the Illumina Exome Enrichment protocol. The captured libraries were sequenced using Illumina HiSeq 2000 Sequencer. The reads were mapped against UCSC hg19 (http://genome.ucsc.edu/) by BWA (http:// bio-bwa.sourceforge.net/). The single nucleotide polymorphisms (SNPs) and indels were detected by SAMTOOLS (http:// samtools.sourceforge.net/). Variants from whole exome sequencing (WES) were filtered such that only novel (or very low frequency 50.1%), coding/splicing, homozygous variants that are within the autozygome of the affected individual and are predicted to be pathogenic were considered as likely causal variants (Alkuraya, 2013 (Alkuraya, , 2016 . Frequency of variants was determined using publicly available variant databases (1000 Genomes, Exome Variant Server and ExAC) as well as a database of 2369 in-house ethnically-matched exomes. Pathogenicity was likely if the mutation is loss-of-function (splicing/truncating) or, in the case of missense/in-frame indels, removes a highly conserved amino acid and is predicted to be pathogenic by the three in silico prediction modules PolyPhen-2, SIFT and CADD.
RT-PCR and immunoblot analysis
To check for the stability of MICU2 transcript, reverse transcription polymerase chain reaction (RT-PCR) was carried out using RNA extracted from fibroblasts derived from patients and controls using RNeasy manufacturer's instruction. Western blot was performed to check for the integrity of MICU2 and MICU1 proteins using commercial antibodies (Abcam ab121499 and Thermo Fisher Scientific pa5-57966). Protein was extracted from the same fibroblasts used for the RT-PCR experiment, by RIPA buffer (Sigma) and protease phosphatase inhibitor (Thermo Fisher Scientific).
Tissue culture and intracellular calcium measurement
Fibroblasts from both affected children and two controls were seeded for 18 h on round coverslips in minimum essential medium Eagle (MEME, Sigma) supplemented with 15% foetal bovine serum (Gibco), 1% glutamine (Gibco) and 1% penicillin-streptomycin (Sigma). Fluorescence laser scanning confocal microscopy of Fluo-4 AM or Rhod-2 AM (Thermo Fischer scientific) loaded cells was used to measure cytosolic and mitochondrial calcium changes, respectively. Briefly, coverslips containing loaded cells were sandwiched between the magnetic plates of a purposely built coverslip holder mounted on a temperature controlled inverted microscope stage adaptor. Serial images were acquired at $1-s intervals. The stimulus (bradykinin, 25 mM) was added during image acquisition and images were stored and subsequently analysed using CLSM software (Zeiss META 510) and Volocity software (Perkin Elmer). Testing the dynamics of the mitochondrial Na + /Ca 2 + exchanger (NLCXm) was pursued using the selective inhibitor CGP-37157 as described previously (Bhosale et al., 2017) . Mitochondrial membrane potential (ÁÉm) was tested using MitoTracker Õ Red CMXRos (Invitrogen, Molecular Probes), the fluorescence intensity of which in living mitochondria is sensitive to ÁÉm (Bhosale et al., 2017) . We also analysed the kinetics of dissipation of ÁÉm by the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP, 1 mM). Oxidative stress was investigated by measuring the effect of externally added H 2 O 2 (0.03%) to cells labelled with MitoSOX TM Red Mitochondrial Superoxide Indicator (Life Technologies) (1 mM, 30 min at 37 C).
Results
Identification of a novel neurological phenotype in a consanguineous family
The index patient (Patient 16DG0621) is an 11.3-year-old girl born at term following an uneventful pregnancy. Although mild hypotonia was noted in infancy with resulting delay in acquiring motor milestones, she showed significant catch-up motor development. However, cognitive development continued to be delayed and she is currently labelled as having severe intellectual disability with severe attention deficit hyperactivity disorder (ADHD). There is no history of abnormal movements. The parents are first cousins with a history of three abortions and a living son with developmental delay and ADHD (see below). Her examination at age 8 years revealed subtle facial dysmorphia, normal growth parameters, and no organomegaly or skeletal changes. Cranial nerves, and tone and power of the extremities were normal. Basic metabolic, biochemical, and haematological indices were normal. Plasma acylcarnitines and amino acids, and urine organic acids were normal. MRI brain revealed gliosis in the parietal periventricular regions bilaterally and multiple T 2 hyperintensity foci scattered within both cerebral hemispheres in a subcortical distribution (Fig. 1) . Magnetic resonance spectroscopy was unremarkable. Chromosomal microarray and clinical exome sequencing did not reveal any pathogenic variants.
Her brother (Patient 16DG0622) is 6.5 years old and was also born following an unremarkable term pregnancy. At age 4 days he developed abnormal eye movement and limb jerks and was admitted to the intensive care unit. Brain CT scan revealed bilateral periventricular haemorrhage and sagittal sinus thrombosis. He received heparin for 6 months and antiepileptic medication. He showed global developmental delay although motor functions were normal. He has significant cognitive impairment and was additionally diagnosed with ADHD. Clinical examination revealed no gross facial dysmorphism and normal height and weight. Head circumference was on the 95th centile. There were no focal neurological signs, neurocutaneous stigmata, or organomegaly. Basic metabolic, haematological, and biochemical labs were unremarkable. Homocysteine level and coagulopathy studies were normal. A follow-up CT brain revealed bilateral thalamic haemorrhage as well as the bilateral intraventricular haemorrhage in addition to supratentorial hydrocephalus. Brain MRI showed deep periventricular encephalomalacia particularly in the left peritrigonal region (Fig. 1) .
Identification of a novel null mutation in MICU2
The consanguinity of the parents and the presence of affected male and female members suggested an autosomal recessive inheritance of a pathogenic variant that the parents share from their common set of grandparents. Autozygome analysis of the two children revealed several shared regions of homozygosity that were considered candidate loci for the purpose of filtering the exome variants (Fig. 2 ). Only one rare/novel homozygous coding/splicing variant was identified within the candidate autozygome: MICU2: NM_152726: c.42G4A:p.W14*. This variant was confirmed to be homozygous in both children and heterozygous in the parents. The nature of the mutation predicts nonsense-mediated decay. However, RT-PCR did not suggest instability of the transcript (Fig. 2) . On the other hand, immunoblot analysis revealed complete absence of the band corresponding to the 43 kD MICU2 as well as the hypothetical 510 kD band representing the truncated protein, which suggests the null nature of the mutation (Fig. 2) . No effect on MICU1 abundance was appreciated using the same assay (Fig. 2) . MICU2 ab -Isabel et al., 2016) . Therefore, we set out to assess the cytosolic and mitochondrial Ca 2 + changes at baseline and in response to receptor-mediated stimulation. In a series of experiments, we demonstrate that bradykinin (25 mM) evoked a significantly and consistently higher cytosolic calcium [Ca 2 + ] i levels in skin fibroblasts isolated from two controls compared to those isolated from the two patients (Fig. 3) . Calcium changes reached maximum ratios of 4.21 AE 0.49 (n = 17) and 2.58 AE 0.16 (n = 27) of prestimulation levels for control and patients cells, respectively (P 5 0.0006). Intramitochondrial calcium concentrations following bradykinin stimulation were probed using the mitochondrial calcium indicator Rhod-2AM (Baumgartner et al., 2009) . At baseline, mitochondria in control cells assumed the normal healthy tubular structure with lower Rhod-2 fluorescence intensity in contrast to mitochondria in patients' cells, which appeared punctate and exhibited higher resting Rhod-2 fluorescence intensity, suggesting a higher resting calcium levels in patients' mitochondria (Supplementary Fig. 1 , P 5 0.0001). A marked difference was also observed between patient and control fibroblasts when exposed to bradykinin. Specifically, normal fibroblasts displayed rapid Ca 2 + influx into the mitochondria (Fig. 3) , with t 1/2 = 13.3 AE 0.75 s. In contrast, mitochondrial calcium influx was significantly prolonged in patients' fibroblasts (t 1/2 = 32.3 AE 3.7 s, P 5 0.0003). Interestingly, however, no significant difference in maximum response levels were observed in the patients' and control cells (Fig. 3) . Taken together, these results suggest that loss of MICU2 leads to [Ca 2 + ] m overload at resting state and decreased cytosolic rise of free Ca 2 + in response to receptor-mediated stimuli. Our results also show that mitochondria from patients deficient in MICU2 retain the capacity to reach comparable calcium levels to controls in response to stimuli albeit at a slower rate.
GAPDH-RT-PCR
We characterized the mitochondrial calcium dynamics in patients with MICU2 mutation using the mitochondrial Na + /Ca 2 + exchanger (NLCXm) inhibitor CGP-37157. NLCXm facilitates efflux of Ca 2 + from mitochondria so blocking it is expected to exacerbate the MICU2 deficiency-induced deregulation of Ca 2 + level in mitochondria shown above. Indeed, we found that CGP-37157 (10 mM) Each scatter plot represents three experiments each involving at least six cells from two patients and two controls. Images were analysed using Ziess LSM 510 Meta software.
induced significant changes in intra-mitochondrial fluorescence consistent with accumulation of Ca 2 + in the mitochondrial [Ca 2 + ] m (Fig. 4B ). We then set out to assess the possibility that MICU2 mutation affected mitochondrial membrane potential (ÁÉm) in cells labelled with MitoTracker Õ Red CMXRos. We used MitoTracker Õ Red because its fluorescence intensity in living mitochondria is sensitive to ÁÉm (Cottet-Rousselle et al., 2011). Resting MitoTracker Õ Red fluorescence intensity was modestly but significantly higher in patients' mitochondria compared to control (P = 0.006) suggesting different ÁÉm. This was further confirmed by analysis of the kinetics of dissipation of ÁÉm by the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP, 1 mM) in patients and control cells. CCCP evoked a rapid depolarization of ÁÉm in control cells reaching 0.58 AE 0.02 of the resting level at 6.04 AE 0.77 s. In contrast CCCP evoked a transient hyperpolarization in patient cells reaching a maximum ratio of 1.33 AE 0.04 at 10.57 AE 1.08 s (Fig. 4A) . Taken together our results suggest that MICU2 mutation is associated with altered ÁÉm.
Finally, we evaluated a potential effect of MICU2 deficiency on the mitochondrial sensitivity to oxidative stress induced by exposure to H 2 O 2 . In a series of experiments, control and patients' cells were labelled with MitoSOX TM Red Mitochondrial Superoxide Indicator and their response to H 2 O 2 was followed by confocal microscopy. Under such conditions patients' cells exhibited significantly higher response to the externally added H 2 O 2 than cells from control subjects (Fig. 4C) . This suggests that patients' mitochondria were more sensitive to oxidative stress than controls.
Discussion
Mitochondria calcium homeostasis is required for several key cellular functions (McCormack et al., 1990; Rizzuto and Pozzan, 2006; Giacomello et al., 2007; Szabadkai and Duchen, 2008) . However, demonstration of the physiological requirement for MCU-regulated mitochondrial Ca 2 + in vivo has been lacking until the report by Logan et al. (2014) . Those authors described several patients with deficiency of MICU1 with a resulting mitochondrial encephalomyopathy phenotype that consists of myopathy with elevated creatine kinase and dystonia due to involvement of the basal ganglia. The cognitive impairment was not pronounced. Indeed, a subsequent report by Lewis-Smith et al. (2016) also emphasized the myopathy phenotype and the mild cognitive involvement. In those reports, mitochondria appeared to be loaded with Ca 2 + at the resting state but displayed impaired influx of Ca 2 + upon stimulation, which leaves unanswered whether MICU1 has inhibitory or a dual inhibitory and stimulatory role as previously suggested (Perocchi et al., 2010; Mallilankaraman et al., 2012b; Csordá s et al., 2013; Plovanich et al., 2013) . Although the patients described with MICU1 mutations had normal respiratory chain analysis and lactate, it was suggested that their typical mitochondrial syndrome may have been caused by impaired energy production due to abnormal pyruvate dehydrogenase activity (Logan et al., 2014) . This was further corroborated by a follow-up study in which MICU1 deficiency was suggested to result in continuous mitochondrial Ca 2 + influx balanced by Ca 2 + efflux through the sodium calcium exchanger (NLCXm) with subsequent inefficient expenditure of energy (Bhosale et al., 2017) .
The two patients we describe in this study are, to the best of our knowledge, the first instance of MICU2 deficiency in humans, which represents a unique opportunity to deduce the physiological function of this component of MCU in vivo. It has been suggested that MICU1 and MICU2 are paralogues with a non-redundant, perhaps opposite role in regulating MCU Patron et al., 2014) . However, the consequence of their depletion individually on mitochondrial Ca 2 + homeostasis has been controversial. The patients described by Logan et al. (2014) and Lewis-Smith et al. (2016) with MICU1 deficiency and the patients we described with MICU2 deficiency demonstrate different cellular pathologies, which may explain the distinct phenotype of the two syndromes (Supplementary Table 1) . Indeed, our results show that fibroblasts from patients deficient in MICU2 resemble those from MICU1-deficient patients in certain aspects but differ in important others. Both MICU1-and MICU2-mutant fibroblasts have apparent Ca 2 + overload during resting states, and retain the capacity to reach maximum intramitochondrial Ca 2 + in response to stimuli. However, unlike MICU1-mutant fibroblasts, MICU2-mutant fibroblasts show significant slowing of Ca 2 + influx. This may be related to a compensatory increased activity of NLCXm. This is supported by demonstrating NLCXm blockage-induced abnormal accumulation of [Ca 2 + ] m , which Bhosale et al. (2017) suggested indicates a futile cycle of Ca 2 + influx and efflux at the resting state. The resulting energy loss of such a futile cycle would be most consequential to tissues with high energy demand. Two additional differences between MICU1 and MICU2 deficiency states include increased sensitivity to oxidative stress and altered ÁÉm, both unique to MICU2-deficient fibroblasts. The high ÁÉm is particularly interesting and we speculate this might be related to increased activity of Na + /Ca 2 + exchanger to reverse the abnormal Ca 2 + concentration. The subsequent increase in matrix Na + will in turn activate Na + /H + exchange resulting in matrix proton overload as proposed recently by Bhosale et al. (2017) . Why this increase in ÁÉm should be unique to MICU2 deficiency despite the similarly overactive Na + /Ca 2 + in MICU1 deficiency, and why it should be augmented by CCCP remain unclear at this point. However, CCCP is known to interfere with mitochondrial Ca 2 + uptake and to induce hyperpolarization under certain conditions (Guzmá n-Grenfell et al., 2000; Beckett et al., 2004; Mallilankaraman et al., 2012a) . It is, therefore, possible to speculate that by clamping the theoretical equilibrium potential for H + (E H , À40 mV), CCCP may bring the plasma membrane potential closer to E H thus activating voltage-dependent calcium channels within the plasma membrane leading to increased cytosolic calcium with the subsequent increase in [Ca 2 + ] m . The latter would exacerbate matrix proton overload leading to the observed hyperpolarization.
Our MICU2-deficient patients lack the hallmarks of classical mitochondrial encephalomyopathy in that they did not have any sign of myopathy, their basal ganglia were conspicuously spared, and their lactic acid levels were consistently normal. In contrast, both patients developed profound encephalopathy with severe cognitive impairment. This potentially highlights an important and non-redundant role of MICU2 in synapse transmission. Although much has been published about the role of MCU in synapse transmission, this remains a contested issue (Marland et al., 2016) . We also do not rule out the possibility that MICU2 deficiency may have resulted in the observed severe CNS phenotype via mechanisms not directly related to the observed cellular phenotypes in this study. Similarly, we should note that the difference in phenotypes between MICU1-and MICU2-deficiency syndromes need not be solely attributed to the discordant cellular phenotypes, and that different tissue distribution between these two MCU components may also play a role.
In conclusion, we add MICU2 to the individual components of MCU whose deficiency results in disease states in humans. The contrast in the phenotypic consequences of MICU1 and MICU2 deficiency supports previously published data on their non-redundant roles in MCU physiology and challenges the notion that their roles are similar. In view of the severe nature of the mutation we report in this study, it remains to be seen what phenotypic consequences milder mutations in MICU2 may have.
